SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...

Credit: Dexcom. The Dexcom Stelo Glucose Biosensor System is an integral CGM intended for individuals 18 years of age and older with or without diabetes who are not on insulin. The Food and Drug ...

Credit: Dexcom. Stelo is an integrated CGM that continuously measures, records, analyzes, and displays glucose values in individuals 18 years of age and older who are not on insulin. Dexcom’s Stelo ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

Oura announced on May 6 that its smart ring has added two new metabolic health features, Meals and Glucose. That’s thanks to a union of the ring’s artificial intelligence with glucose data from Dexcom ...

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Stelo, an enterprise software company, has filed suit in Federal District Court for the Central District of California against San Diego-based Dexcom, Inc.